This communication deals, in brief, with the toxic manifestations observed in 270 patients treated with mapharsen in various dosages by the drip method of therapy.
The toxic manifestations in 111 patients treated with neoarsphenamine have already been reported.1 In the neoarsphenamine series, there were one fatality due to hemorrhagic encephalitis and a rather high incidence of polyneuritis (38 per cent). This led us to the substitution for neoarsphenamine of another arsenical, namely, mapharsen, which we had reason to believe might prove less toxic and perhaps equally efficacious therapeutically, if we were to judge by our experience with a large series of patients with early syphilis treated by the routine method.
In the 270 patients for whom treatment with mapharsen has been completed, there has been no death due to the treatment. In 1 patient in the series hemorrhagic encephalitis developed, which will be discussed later. With this single exception
CHARGIN L. TOXICOLOGIC MANIFESTATIONS. Arch Derm Syphilol. 1940;42(2):248–252. doi:10.1001/archderm.1940.01490140012003
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.